Truist Securities Maintains Buy on HCA Healthcare, Lowers Price Target to $300
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has maintained a 'Buy' rating on HCA Healthcare (NYSE:HCA), but lowered the price target from $340 to $300.
October 25, 2023 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a 'Buy' rating on HCA Healthcare, but lowered the price target from $340 to $300.
The news is directly related to HCA Healthcare. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100